April 19th 2024
Your daily dose of the clinical news you may have missed.
April 17th 2024
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
April 11th 2024
The additional indication for benralizumab was supported by data from the phase 3 TATE trial.
March 7th 2024
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
February 29th 2024
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
New Research Highlights Specific Allergens that May Predispose Sensitized Children with Asthma to Upper Respiratory Infections
AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improved Lung Function and Asthma Control, According to New Data
AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.
Cannabis Use and Risk of Prevalent Asthma: Daily Dose
Depression Severity Linked to Higher Odds of Asthma, COPD, and Respiratory Symptoms
The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.
Use of Cannabis Linked to High Risk of Prevalent Asthma: New Findings
Past month use of cannabis was associated with 43% greater odds of asthma than no use of the drug; odds were 2-fold greater with use of blunts.
Dupilumab Safe for Patients with Moderate-to-Severe Asthma for up to 6 Years
New data suggest that dupilumab is safe for long-term use among patients with moderate-to-severe asthma or OCS-dependent severe asthma.
Risk for Incident Asthma and Exacerbations Increases with Atopic Dermatitis in Dose-Dependent Fashion: Study
The risk of asthma and poor outcomes was even greater among children with both conditions than among adults in this first study to compare the 2 populations.
Dupilumab Reduces Nighttime Symptoms, Sleep Disturbance in Severe T2 Asthma
Use of dupilumab also eliminated the need for use of a rescue inhaler in more than one-third of treated patients and the number of inhalations needed for others.
Daily Dose: Global Disparities in Asthma Prevalence
Low Estimated Burden of Asthma in Low- and Middle-Income Countries Likely Reflects Underdiagnosis, Underreporting
A new meta-analysis found prevalence of asthma higher in countries with better air quality, higher income status, and health care access.
Daily Dose: Maintenance Therapy Utilization Suboptimal Before Asthma Exacerbations
Use of Maintenance Therapy Suboptimal Before Asthma Exacerbations, New Research Finds
Many patients with moderate-to-severe asthma may not be using inhaled corticosteroids along with rescue medications to avoid serious disease exacerbations.
Final Thoughts on Treatment of Asthma
Raffi Tachdjian, MD, MPH, FAAAAI, FACAAI; Dareen D. Siri, MD, FAAAAI, FACAAI; Nicole Chase, MD, FAAP, FACAAI, FAAAAI; and Andrew White, MD, give final thoughts on asthma management, considering the current treatment landscape.
Role of Biomarkers in Asthma
Experts outline biomarkers to measure asthma, highlighting eosinophil count and fractional exhaled nitric oxide levels.
Trends in Biologic Treatment of Asthma
Experts discuss the use of biologic treatment in asthma by primary care physicians vs pulmonology specialists as well as overcoming barriers to biologic use through patient and physician education.
Switching Biologic Treatment in Asthma
Experts comment on switching from 1 biologic treatment to another, as well as combining biologics with steroids or other treatments in asthma.
Optimizing Biologic Treatment Selection in Asthma
Andrew White, MD, discusses choosing the right biologic for patients with severe asthma, considering factors such as asthma comorbidities as well as patient preference.
Use of Dupilumab in Treatment of Asthma
Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the efficacy and safety of dupilumab for the treatment of asthma, as well as which patients are good candidates for dupilumab.
Dual Inhibition of Interleukins by Dupilumab in Asthma
Nicole Chase, MD, FAAP, FACAAI, FAAAAI, provides an overview of the difference between single and dual inhibition of interleukins, focusing on dupilumab as a dual inhibitor for asthma treatment.
Use of Biologic Treatment in Asthma
Experts discuss the use of biologic agents to manage asthma and describe the mechanisms of action of different biologics.
Overuse of Oral Corticosteroids in Asthma
Medical expert highlights the risk of overuse of oral corticosteroids in the management of asthma and reviews alternative treatment options.
Use of Guidelines to Classify Asthma
Andrew White, MD, reviews the definition of difficult-to-treat or severe asthma as outlined in the GINA (Global Initiative for Asthma) guidelines.
Treatment Selection for Severe Asthma
Experts discuss the process of choosing a treatment plan for patients with severe allergic or eosinophilic asthma.
Treatment Landscape of Asthma
Andrew White, MD, provides an overview of the asthma treatment landscape, focusing on inhaled and oral corticosteroids, as well as biologic and nonbiologic agents.
Predicting Exacerbation of Asthma
Dareen D. Siri, MD, FAAAAI, FACAAI, reviews the tools available to predict the exacerbation of asthma, highlighting spirometry and biomarkers as effective tools.
Multidisciplinary Care for Patients With Asthma
A panel of experts comment on primary care vs specialist care for patients with asthma, and when patients should be referred to a specialist.
Signs of Severe Asthma and the Underlying Pathophysiology
Reviewing the symptoms of coughing, wheezing, and shortness of breath as a product of an overactive immune system and as a sign of asthma.
Role of Type 2 Inflammation in Asthma
Nicole Chase, MD, FAAP, FACAAI, FAAAAI, describes the mechanism of type 2 inflammation and comments on it being a prominent issue among patients with asthma.
Overview of Asthma
Andrew White, MD, provides an overview of the difference of asthma endotypes and phenotypes as a way to define and diagnose asthma.